Fulgent Genetics Q3 2025 earnings beat expectations with a surprise profit, causing a 4% pre-market stock surge. The company also raised its full-year guidance.
Fulgent Genetics has seen its fortunes shift since the pandemic. Is it a solid investment or a risky bet? Join us as we break down its performance and management decisions.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
